• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Summit Therapeutics Inc. (Amendment)

    2/14/23 4:03:10 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SMMT alert in real time by email
    SC 13G/A 1 polar-smmt123122a2.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*



    Summit Therapeutics Inc.

    (Name of Issuer)

     

    Common Stock, $0.01 par value per share

    (Title of Class of Securities)

     

    86627T108

    (CUSIP Number)

     

     

    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  86627T108
     SCHEDULE 13G/A
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Polar Capital Holdings Plc
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United Kingdom
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.0%
    12
    TYPE OF REPORTING PERSON
     
    HC

     


     

    CUSIP No.  86627T108
     SCHEDULE 13G/A
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Polar Capital LLP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United Kingdom
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0.0%
    12
    TYPE OF REPORTING PERSON
     
    IA

     


     

     

    CUSIP No. 86627T108
     SCHEDULE 13G/A
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    Summit Therapeutics Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    2882 Sand Hill Road, Suite 106

    Menlo Park, CA 94025

    Item 2.(a) Name of Person Filing:

    Polar Capital Holdings Plc

    Polar Capital LLP

     

    Item 2.(b,) Address of Principal Business Office:

    16 Palace Street

    London, SW1E 5JD

     

    Item 2.(c) Citizenship:

    United Kingdom

      

    Item 2.(d) Title of Class of Securities

    Common Stock, $0.01 par value per share (the “Common Stock”)

     

    Item 2.(e) CUSIP No.:

    86627T108

     

    CUSIP No.  86627T108
     SCHEDULE 13G/A
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) o A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 86627T108
     SCHEDULE 13G/A
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1:

    Polar Capital Holdings Plc

    (a) Amount beneficially owned: 0

    (b) Percent of class: 0.0%*

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: 0

    (ii) Shared power to vote or to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 0

    (iv) Shared power to dispose or to direct the disposition of: 0

     

    Polar Capital LLP

    (a) Amount beneficially owned: 0

    (b) Percent of class: 0.0%*

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: 0

    (ii) Shared power to vote or to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 0

    (iv) Shared power to dispose or to direct the disposition of: 0

     

    * Based on 201,321,175 shares, which is the total number of shares outstanding as reported in the Issuer's Form 10-Q on November 09, 2022.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person 

    Information for each Subsidiary is incorporated on the respective cover pages..

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 86627T108
     SCHEDULE 13G/A
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2023

     

     

     

    POLAR CAPITAL HOLDINGS PLC

           
      By:  Nicholas Farren
       

    Name: Nicholas Farren

    Title: Chief Operating Officer 

           
     

    POLAR CAPITAL LLP

           
      By:  Nicholas Farren
       

    Name: Nicholas Farren

    Title: Chief Operating Officer 

           

     

     
    CUSIP No. 86627T108
     SCHEDULE 13G/A
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: February 14, 2023

     

     

     

    POLAR CAPITAL HOLDINGS PLC

           
      By:  Nicholas Farren
       

    Name: Nicholas Farren

    Title: Chief Operating Officer 

           
     

    POLAR CAPITAL LLP

           
      By:  Nicholas Farren
       

    Name: Nicholas Farren

    Title: Chief Operating Officer

           
    Get the next $SMMT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SMMT

    DatePrice TargetRatingAnalyst
    5/22/2026Buy → Neutral
    H.C. Wainwright
    4/8/2026$45.00Buy
    Stifel
    3/16/2026$15.00Buy → Hold
    Jefferies
    12/17/2025$18.00Underweight → Equal Weight
    Barclays
    11/18/2025Peer Perform
    Wolfe Research
    9/17/2025$13.00Underweight
    Barclays
    9/4/2025$40.00Buy
    Guggenheim
    8/19/2025$21.00Neutral
    Piper Sandler
    More analyst ratings

    $SMMT
    SEC Filings

    View All

    Summit Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Summit Therapeutics Inc. (0001599298) (Filer)

    6/12/26 4:11:17 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Summit Therapeutics Inc. (0001599298) (Filer)

    6/11/26 7:44:02 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3ASR filed by Summit Therapeutics Inc.

    S-3ASR - Summit Therapeutics Inc. (0001599298) (Filer)

    6/9/26 4:33:24 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SMMT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026

    Conference Call to Be Held at 4:30 p.m. EDT Summit Therapeutics Inc. (NASDAQ:SMMT) will host a conference call to announce its second quarter 2026 financial results and provide an update on operational progress on Thursday, July 23, 2026. The call is scheduled to take place at 4:30 p.m. EDT. The live and archived webcast can be accessed through the Investor Information section of the company’s website, www.smmttx.com. About Summit Therapeutics Inc. Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of lif

    7/16/26 8:00:00 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.

    Summit Therapeutics Inc. (NASDAQ:SMMT) today announced it has signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole, an investigational Phase III precision antibiotic owned by Summit. Biossil is an artificial intelligence (AI)-native biopharma company focused on advancing late-stage programs in life-threatening indications with urgent unmet medical needs. Previously, ridinilazole was evaluated in Summit’s Phase III Ri-CoDIFy study for the treatment of patients suffering from C. difficile infection (C. diff. infection or CDI), an area of high unmet need. The study showed that ridinilazole resulted in a higher observed Sustained Clinical Response (SCR) rate than

    7/14/26 7:00:00 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The New War on Cancer: Four Public Companies Helping Lead a Medical Revolution

    DENVER, June 25, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Cancer treatment is undergoing one of the most significant transformations in modern medical history. For decades, physicians relied primarily on surgery, radiation, and chemotherapy. While those therapies have saved countless lives, a new generation of biotechnology companies is working to make cancer treatment smarter, more targeted, and potentially more effective. Rather than simply attacking rapidly dividing cells, researchers are developing therapies designed to identify specific genetic mutations, harness the immune system, and deliver treatments directly to cancer cells while minimizing damage to healthy tissue. Seve

    6/25/26 11:39:11 AM ET
    $BNTX
    $SMMT
    $CGON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $SMMT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Zanganeh Mahkam bought $49,987,200 worth of shares (3,810,000 units at $13.12) (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    6/12/26 2:35:11 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Duggan Robert W bought $49,987,200 worth of shares (3,810,000 units at $13.12), increasing direct ownership by 0.67% to 573,883,879 units (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    6/12/26 12:28:50 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Duggan Robert W bought $1,460,000 worth of shares (100,000 units at $14.60) (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    6/4/26 6:08:26 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SMMT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Zanganeh Mahkam bought $49,987,200 worth of shares (3,810,000 units at $13.12) (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    6/12/26 2:35:11 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Duggan Robert W bought $49,987,200 worth of shares (3,810,000 units at $13.12), increasing direct ownership by 0.67% to 573,883,879 units (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    6/12/26 12:28:50 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Duggan Robert W bought $1,460,000 worth of shares (100,000 units at $14.60) (SEC Form 4)

    4 - Summit Therapeutics Inc. (0001599298) (Issuer)

    6/4/26 6:08:26 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SMMT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Summit Therapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Summit Therapeutics from Buy to Neutral

    5/22/26 8:27:33 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Summit Therapeutics with a new price target

    Stifel initiated coverage of Summit Therapeutics with a rating of Buy and set a new price target of $45.00

    4/8/26 8:38:26 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics downgraded by Jefferies with a new price target

    Jefferies downgraded Summit Therapeutics from Buy to Hold and set a new price target of $15.00

    3/16/26 8:36:55 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SMMT
    Leadership Updates

    Live Leadership Updates

    View All

    Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

    Mr. LaCaze Brings Over 35 Years of Executive Leadership Experience in the Biopharmaceutical Industry Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Robert LaCaze has joined Summit Therapeutics as Chief Commercial Officer, reporting to Manmeet S. Soni, Chief Operating Officer and Chief Financial Officer, effective immediately. Robert W. Duggan and Dr. Maky Zanganeh, Co-CEOs of Summit Therapeutics, stated, "Robert's extensive experience and proven track record in the oncology space make him an exceptional addition to our team. His leadership will be instrumental as we seek to bring ivonescimab to patients in need. We are truly excited to have

    3/17/25 4:24:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors

    Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Jeff Huber has been appointed to its Board of Directors, effective immediately. "It is an honor to add Jeff Huber to our excellent, diverse group of board members," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "Jeff's executive leadership experience in healthcare and technology and his countless accomplishments evidence his ability to translate what's possible into transformational success. As we seek to change the standard of care for solid tumors based on the potential of ivonescimab, we are thrilled to supplement our outstanding leadership team with a board member

    6/27/24 4:15:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors

    Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. "We are excited to add Dr. Ronaghi to complement our excellent group of current board members," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "Mostafa has valuable experience in translating innovative concepts in genomics and sequencing that ultimately lead to advancements in patient care through his work at Illumina, Grail, and his continuing ventures. As we intend to maximize the potential of ivonescimab, we are excited to add the acumen and expertise that Mostafa can bring to

    4/11/24 4:30:00 PM ET
    $ILMN
    $SMMT
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $SMMT
    Financials

    Live finance-specific insights

    View All

    Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026

    Conference Call to Be Held at 4:30 p.m. EDT Summit Therapeutics Inc. (NASDAQ:SMMT) will host a conference call to announce its second quarter 2026 financial results and provide an update on operational progress on Thursday, July 23, 2026. The call is scheduled to take place at 4:30 p.m. EDT. The live and archived webcast can be accessed through the Investor Information section of the company’s website, www.smmttx.com. About Summit Therapeutics Inc. Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of lif

    7/16/26 8:00:00 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

    Ivonescimab Plus Chemotherapy Reduced the Risk of Death by 34% Compared to Tislelizumab Plus Chemotherapy; Hazard Ratio 0.66 First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in 1L NSCLC Tolerable Safety Profile Consistent with Prior Clinical Trial Results Simultaneous Publication of Latest Ivonescimab HARMONi-6 Results in The Lancet Summit Conference Call to Be Held at 7:00 a.m. ET on Monday, June 1, 2026 Summit Therapeutics Inc. (NASDAQ:SMMT) today announced positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducte

    5/31/26 9:06:00 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026

    Overall Survival Data to be Featured at ASCO 2026 Plenary Session as Late-Breaking Abstract from HARMONi-6, a Phase III Study in 1L Squamous NSCLC in China Update Conference Call to be Held on June 1, 2026 after ASCO Plenary Session HARMONi-3 Squamous Cohort of Global Phase III 1L NSCLC Study: Final PFS Data Expected in Second Half of 2026 with Interim OS Analyses Planned HARMONi-3 Non-Squamous Cohort of Global Phase III 1L NSCLC Study: PFS Data Expected in the First Half 2027 Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on clinical and operational progress for the first quarter ended March 31, 2

    4/30/26 4:32:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SMMT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Summit Therapeutics Inc.

    SC 13D/A - Summit Therapeutics Inc. (0001599298) (Subject)

    9/13/24 5:54:25 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Summit Therapeutics Inc. (Amendment)

    SC 13D/A - Summit Therapeutics Inc. (0001599298) (Subject)

    3/13/23 4:51:59 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Summit Therapeutics Inc. (Amendment)

    SC 13D/A - Summit Therapeutics Inc. (0001599298) (Subject)

    2/16/23 4:01:07 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care